Nestlé has finally divested the peanut allergy business acquired in 2019 to much fanfare after the treatment spectacularly failed to live up to its blockbuster potential.

Heralded as a potential blockbuster, Nestlé's acquisition of Palforzia has proved to be a very expensive mistake.

NHS England and Improvement (NHSE&I) agreed 16 pricing and access deals with drug companies in 2021, ten of which can be considered ‘smart.’ The fact that these were achieved against a backdrop of COVID-19 is seen as impressive.

The decision by IQWiG could have an impact on how Palforzia is priced if the findings are upheld.